Formuepleje A/S’s Vertex Pharmaceuticals VRTX Stock Holding History

Formuepleje A/S’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.2M	Buy	+2,409	New	+$1.07M	0.09%	78
2023 Q4	–	Sell	-46,326	Closed	-$16.1M	–	94
2023 Q3	$16.1M	Sell	46,326 -1,102	-2%	-$385K	1.49%	20
2023 Q2	$16.7M	Sell	47,428 -34,421	-42%	-$11.6M	1.46%	21
2023 Q1	$25.8M	Buy	81,849 +10,137	+14%	+$3.04M	1.89%	19
2022 Q4	$20.7M	Buy	71,712 +31,833	+80%	+$9.7M	1.75%	18
2022 Q3	$11.5M	Buy	39,879 +25,329	+174%	+$7.29M	0.94%	38
2022 Q2	$4.1M	Sell	14,550 -3,884	-21%	-$1.04M	0.25%	54
2022 Q1	$4.73M	Sell	18,434 -4,955	-21%	-$1.18M	0.21%	56
2021 Q4	$5.14M	Sell	23,389 -3,953	-14%	-$769K	0.2%	59
2021 Q3	$4.96M	Buy	27,342 +16,144	+144%	+$3.15M	0.2%	56
2021 Q2	$2.26M	Buy	+11,198	New	+$2.34M	0.09%	62

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Formuepleje A/S's VRTX Position: Q2 2026 in Review

Formuepleje A/S opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 2,409 shares worth $1.2M. The stake represents 0.09% of the portfolio and ranks #78 among its holdings. This is a return to the name: Formuepleje A/S previously reported a position in VRTX as recently as Q3 2023.

Formuepleje A/S first reported a position in VRTX in Q2 2021 and has held it in 11 quarters since. The position peaked at $25.8M in Q1 2023. 1,754 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Formuepleje A/S held 2,409 shares of Vertex Pharmaceuticals worth $1.2M as of Q2 2026.
Vertex Pharmaceuticals was a new Formuepleje A/S position in Q2 2026.
Vertex Pharmaceuticals made up 0.09% of Formuepleje A/S's portfolio in Q2 2026, its #78 holding.
Formuepleje A/S first reported a position in Vertex Pharmaceuticals in Q2 2021 and has held it in 11 quarters since.
Formuepleje A/S's Vertex Pharmaceuticals position peaked at $25.8M in Q1 2023.
1,754 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Formuepleje A/S's 13F filing for Q2 2026, filed 27 Aug 2026.